Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mark Clemons

Showing results (191-200 of 267) with videos related to

Pageof 27
Sort By:
Breast Cancer Research and Treatment|October 27, 2016
Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic reviewRicardo Fernandes, Sasha Mazzarello, Carol Stober, et al.
Current Oncology (Toronto, Ont.)|August 25, 2023
A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast CancerRicardo Fernandes, Terry L Ng, Mashari Jemaan Alzahrani, et al.
Molecular and Cellular Biology|May 31, 2012
Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytesSébastien Tabariès, Fanny Dupuy, Zhifeng Dong, et al.
Health Science Reports|December 23, 2021
Oral magnesium supplements for cancer treatment-induced hypomagnesemia: Results from a pilot randomized trialArif Awan, Bassam Basulaiman, Carol Stober, et al.
Breast Cancer Research and Treatment|August 9, 2019
A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patientsAngel Arnaout, Susan J Robertson, Gregory R Pond, et al.
The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique|August 11, 2004
Do physicians follow systemic treatment and funding policy guidelines?Mark Clemons, Katherine Enright, Annemarie Cesta, et al.
Journal of Global Oncology|September 23, 2018
Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic ReviewRicardo Fernandes, Sasha Mazzarello, Carol Stober, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2011
Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PALAmanda Caissie, Janet Nguyen, Emily Chen, et al.
The Lancet. Oncology|August 25, 2011
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyKaren A Gelmon, Marc Tischkowitz, Helen Mackay, et al.
Current Oncology (Toronto, Ont.)|June 2, 2021
Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate CancerMegan M Tu, Mark Clemons, Carol Stober, et al.
Pageof 27

Showing results (191-200 of 267) with videos related to

Sort By:
Pageof 27
Breast Cancer Research and Treatment|October 27, 2016
Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic reviewRicardo Fernandes, Sasha Mazzarello, Carol Stober, et al.
Current Oncology (Toronto, Ont.)|August 25, 2023
A Multi-Centre Randomized Study Comparing Two Standard of Care Chemotherapy Regimens for Lower-Risk HER2-Positive Breast CancerRicardo Fernandes, Terry L Ng, Mashari Jemaan Alzahrani, et al.
Molecular and Cellular Biology|May 31, 2012
Claudin-2 promotes breast cancer liver metastasis by facilitating tumor cell interactions with hepatocytesSébastien Tabariès, Fanny Dupuy, Zhifeng Dong, et al.
Health Science Reports|December 23, 2021
Oral magnesium supplements for cancer treatment-induced hypomagnesemia: Results from a pilot randomized trialArif Awan, Bassam Basulaiman, Carol Stober, et al.
Breast Cancer Research and Treatment|August 9, 2019
A randomized, double-blind, window of opportunity trial evaluating the effects of chloroquine in breast cancer patientsAngel Arnaout, Susan J Robertson, Gregory R Pond, et al.
The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique|August 11, 2004
Do physicians follow systemic treatment and funding policy guidelines?Mark Clemons, Katherine Enright, Annemarie Cesta, et al.
Journal of Global Oncology|September 23, 2018
Primary Febrile Neutropenia Prophylaxis for Patients Who Receive FEC-D Chemotherapy for Breast Cancer: A Systematic ReviewRicardo Fernandes, Sasha Mazzarello, Carol Stober, et al.
International Journal of Radiation Oncology, Biology, Physics|December 17, 2011
Quality of life in patients with brain metastases using the EORTC QLQ-BN20+2 and QLQ-C15-PALAmanda Caissie, Janet Nguyen, Emily Chen, et al.
The Lancet. Oncology|August 25, 2011
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyKaren A Gelmon, Marc Tischkowitz, Helen Mackay, et al.
Current Oncology (Toronto, Ont.)|June 2, 2021
Cost-Effectiveness Analysis of 12-Versus 4-Weekly Administration of Bone-Targeted Agents in Patients with Bone Metastases from Breast and Castration-Resistant Prostate CancerMegan M Tu, Mark Clemons, Carol Stober, et al.
Pageof 27